Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXA-CoV2
- Development stage
- Unknown
- Lead developer
- Vaxart
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
VXA-CoV2 is an investigational oral tablet vaccine developed by Vaxart, designed to protect against the XBB strain of COVID-19. It is administered orally, distinguishing it from injectable vaccines. The vaccine aims to induce an immune response to prevent or mitigate COVID-19 caused by the XBB variant.
- Other names
- Vaxart oral COVID-19 vaccineVaxart XBB oral pill vaccineVaxart XBB.1.5 oral vaccine
Beyond the preview
Go deeper on VXA-CoV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXA-CoV2.